BIOMAT Database Logo BIOMAT Database Logo

FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers. 2024

Asher Mullard

UI MeSH Term Description Entries

Related Publications

Asher Mullard
FDA approves first stem-cell therapy.
December 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Asher Mullard
Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges.
August 2022, Cancers,
Asher Mullard
FDA approves first cell therapy for wrinkle-free visage.
August 2011, Nature biotechnology,
Asher Mullard
Paired tumour infiltrating lymphocyte (TIL) and tumour cell line from bladder cancer: a new approach to study tumour immunology in vitro.
January 1991, European journal of cancer (Oxford, England : 1990),
Asher Mullard
Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.
October 2010, Journal of immunotherapy (Hagerstown, Md. : 1997),
Asher Mullard
Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.
May 1998, Clinical and experimental immunology,
Asher Mullard
FDA approves irinotecan as first-line therapy for colorectal cancer.
May 2000, Oncology (Williston Park, N.Y.),
Asher Mullard
A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma.
February 1995, British journal of cancer,
Asher Mullard
FDA Approves Second CAR T-cell Therapy.
January 2018, Cancer discovery,
Asher Mullard
FDA approves first biologic treatment for sepsis.
January 2002, FDA consumer,
Copied contents to your clipboard!